Agranulocytosis: An adverse effect of allopurinol treatment

Italian Journal of Medicine

Volumn 5, Issue 2, 2011, Pages 120-123

  Mari, Elisa ^a   Ricci, Franco ^a   Imberti, Davide ^a   Gallerani, Massimo ^a  

^a S ANNA HOSPITAL   (Italy)

Author keywords

Agranulocytosis; Allopurinol; Hyperuricaemia

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; CANRENONE; DUTASTERIDE; FUROSEMIDE; MEPREDNISONE; PREDNISONE; URIC ACID;

AGED; AGRANULOCYTOSIS; ANTIBIOTIC THERAPY; ARTICLE; ASTHENIA; BLOOD PRESSURE; BODY TEMPERATURE; CASE REPORT; CHRONIC KIDNEY FAILURE; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ESOPHAGEAL ADENOCARCINOMA; FEVER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; HYPERURICEMIA; MALE; PROSTATE HYPERTROPHY; PULSE RATE; REHYDRATION; TACHYPNEA;

EID: 79957923059     PISSN: 18779344     EISSN: 18779352     Source Type: Journal    
DOI: 10.1016/j.itjm.2011.02.006     Document Type: Article

References (28)

1. Andrès E, Maloisel F. Idiosyncratic drug-induced agranulocytosis or acute neutropenia. Curr Opin Hematol 2008;15(1):15-21. (Pubitemid 350191024)
2. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006;58(1):87-114.
3. Pontikoglou C, Papadaki HA. Idiosyncratic drug-induced agranulocytosis: the paradigm of deferiprone. Hemoglobin 2010;34(3):291-304.
4. Product Information: Allopurinol oral tablets. Corona, CA: Watson Laboratories. Available from: http://pi.watson.com/data--stream.asp?product- group=1197&p=pi&language=E.
5. Product Information: Allopurinol. Dosage form: tablet, coated. March 2009. Available from: http://www.drugs.com/pro/allopurinol.html.
6. Wilkinson DG. Allopurinol and agranulocytosis. Lancet 1977; 2(8051):1282-3.
7. McInnes GT, Lawson DH, Jick H. Acute adverse reactions attributed to allopurinol in hospitalised patients. Ann Rheum Dis 1981;40(3):245-9. (Pubitemid 11122536)
8. Rosenbloom D, Gilbert R. Reversible flu-like syndrome, leukopenia, and thrombocytopenia induced by allopurinol. Drug Intell Clin Pharm 1981;15(4):286-7. (Pubitemid 11069603)
9. Shinohara K, Okafuji K, Ayame H, Tanaka M. Aplastic anemia caused by allopurinol in renal insufficiency. Am J Hematol 1990;35(1):68. (Pubitemid 20254390)
10. Allopurinol ADRs in Sweden include fatal aplastic anemia. Reactions 2001; 849:4.
11. Conrad ME. Fatal aplastic anemia associated with allopurinol therapy. Am J Hematol 1986;22(1):107-8. (Pubitemid 16130308)
12. Kim YW, Park BS, Ryu CH, Park SJ, Kang SW, Kim YH, et al. Allopurinol-induced aplastic anemia in a patient with chronic kidney disease. Clin Nephrol 2009;71(2):203-6.
13. Shapiro S. Letter: Allopurinol and bone-marrow depression. Lancet 1974;2(7877):412.
14. Boston Collaborative Drug Surveillance Program. Allopurinol and cytotoxic drugs. Interaction in relation to bone marrow depression. JAMA 1974;227(9):1036-40.
15. Lin YW, Okazaki S, Hamahata K, Watanabe K, Usami I, Yoshibayashi M, et al. Acute pure red cell aplasia associated with allopurinol therapy. Am J Hematol 1999;61(3):209-11. (Pubitemid 29297892)
16. Chao SC, Yang CC, Lee JY. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease. Ann Pharmacother 2005;39(9):1552-6. (Pubitemid 41197141)
17. Greenberg MS, Zambrano SS. Aplastic agranulocytosis after allopurinol therapy. Arthritis Rheum 1972;15(4):413-6.
18. Hawson GA, Bain BJ. Allopurinol and agranulocytosis. Med J Aust 1980;1(6):283-4.
19. Krulik M, Fkeury J, Audebert AA, Zylberait D, Debray J. Agranulocytosis secondary to a treatment with tisopurine. Nouv Presse Med 1980;9(33):2351.
20. Lee EJ, Kueh YK. Allopurinol-induced skin reactions and agranulocytosis. Singapore Med J 1982;23(3):178-80.
21. Scobie IN, MacCuish AC, Kesson CM, McNeil IR. Neutropenia during allopurinol treatment in total therapeutic starvation. Br Med J 1980;280(6224):1163. (Pubitemid 10116202)
22. Schär B, Meier C, Affolter H. Drug-induced (probably allopurinol) agranulocytosis. Case report and discussion. Schweiz Med Wochenschr 1994;124(13):545-9. (Pubitemid 24110250)
23. Kim JK, Lee YK, Noh JW, Ahn BM, Kim JH, Jung YO, et al. Allopurinol-induced agranulocytosis in a patient on peritoneal dialysis. Korean J Med 2009;76:365-9.
24. Rete Nazionale di Farmacovigilanza, Italia. Available from: https://nsis.sanita.it/ACCN/accessportalnsis/.[Accessed 2010, October 7].
25. Medicines and Healthcare Products Regulatory Agency. Available from: http://www.mhra.gov.uk/index.htm.[Accessed 2010, October 7].
26. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45. (Pubitemid 12149145)
27. Tavassoli N, Duchayne E, Sadaba B, Desboeuf K, Sommet A, Lapeyre-Mestre M, et al. Detection and incidence of drug-induced agranulocytosis in hospital: a prospective analysis from laboratory signals. Eur J Clin Pharmacol 2007;63(3):221-8. (Pubitemid 46237580)
28. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76(1):47-56. (Pubitemid 14216359)